Compared with traditional attenuated/inactivated virus vaccines and subunit protein adjuvant vaccines, mRNA vaccines have the advantages of lower development costs, shorter development cycles, higher safety, simpler processes, and stronger efficacy. Moreover, the natural adjuvant effect of mRNA vaccines can stimulate robust cellular immunity, particularly effective in preventing many infectious diseases, especially recurring latent infections. mRNA technology has become the ideal choice for the development of new generation vaccines and the iteration of traditional vaccines.
EnoBio provides a comprehensive solution with independent intellectual property rights, covering the entire chain from antigen design to clinical sample production and regulatory submission. Customers can choose integrated or single-module/technical solutions according to their needs, including AI-mediated antigen protein design (DMC.AI platform), antigen mRNA design and synthesis, mRNA-LNP lyophilization process (globally leading nanoformulation thermal stability technology1), immune-enhancing cap analogs, targeted LNP delivery systems, and immune-enhancing UTR and poly A tails, among others. By combining the aforementioned proprietary technologies, key raw materials, and research and development production equipment supply chain,EnoBio can not only address the challenges of mRNA vaccine stability and comprehensive product costs but also meet customers' needs for the development and independent control of various vaccines across the entire chain.
